What's Going On With Cancer-Focused Monopar Therapeutics Stock Today?
Portfolio Pulse from Vandana Singh
Monopar Therapeutics Inc (NASDAQ:MNPR) shares surged 67.30% to $0.95 on high volume after announcing promising preclinical data for its MNPR-101 radiopharmaceutical program targeting cancers. The program showed significant tumor uptake and near-complete tumor elimination with a single injection. Additionally, Monopar received clearance in Australia to commence a Phase 1 trial of MNPR-101-Zr in patients with advanced cancers.
February 22, 2024 | 6:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Monopar Therapeutics Inc's stock surged due to promising preclinical data for its MNPR-101 program and the commencement of a Phase 1 trial in Australia.
The significant increase in Monopar Therapeutics Inc's stock price can be attributed to the positive preclinical data for its MNPR-101 program, which targets a wide range of cancers. The clearance to commence a Phase 1 trial in Australia further boosts investor confidence in the potential of MNPR-101, leading to a surge in stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100